Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 245 recruiting now early-phase tilt #5 of 28,707 conditions

Depression: early-phase trial registry

245 of 687 indexed Depression trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #5 of 28,707 conditions by registered trial count.

687 US clinical trials · 245 currently recruiting · #5 of 28,707 conditions by registered trial count

Depression: 687 US clinical trials tracked, 245 recruiting.

Depression is the subject of 687 registered US clinical trials on ClinicalTrials.gov, 245 of them currently open to new participants. 70 are in Phase 3-4 (later-stage) and 111 in Phase 1-2 (earlier-stage). The most active sponsor is Massachusetts General Hospital, running 29 of these trials.

Enrollment posture brief

Registry condition depression

OPEN 245 | RECR 36% | LATE 70 | EARLY 111 | RANK #5 | SPON 29

Nearest open-share peer: Pancreatic Cancer (36% recruiting · 283 trials)

Cancer44.9%Prostate Cancer36.7%Depression (this)36%Hypertension32.2%HIV Infections9.1%
Open-enrollment share among volume-matched conditions near Depression

Depression lists 245 open slots (36% of 687 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Depression on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Depression recruits in line with its size-band peers.

    245 of 687 indexed trials (35.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Depression trials is spread across many organizations.

    Massachusetts General Hospital accounts for 29 of 687 trials (4.2%). 231 distinct sponsors appear on at least one study for this condition label.

  3. Typical Depression enrolment sits around 100 participants.

    Median target enrolment is 100 among the 680 trials that report a genuine target (sentinel values excluded). 331 of those (48.7%) plan for fewer than 100 participants.

  4. Depression research is mostly interventional.

    618 interventional and 69 observational studies make up this index (90% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 141Phase 270Phase 329Phase 441

Open and recent trials

687 total, page 11 of 14

COMPLETED NA 80 participants

Hyperthermic Yoga for Depressive Symptoms

Massachusetts General Hospital

NCT02607514

COMPLETED NA 78 participants

The Effect of Exercise on Mood After Traumatic Brain Injury

University of Washington

NCT00571545

COMPLETED 76 participants

Assessing Anterior Cingulate Brain Activity in People With Late-Life Depression

Weill Medical College of Cornell University

NCT00926653

COMPLETED NA 75 participants

A Randomized-Controlled Trial to Investigate the Effect of a Novel Music Therapy Application to Reduce Anxiety and Stress

SoundMind

NCT06021821

COMPLETED Phase 4 75 participants

Study of 6(S)-5-MTHF Among Selective Serotonin Reuptake Inhibitor-Resistant Outpatients With Major Depressive Disorder

George I. Papakostas

NCT00955955

COMPLETED NA 75 participants

The "PC-LIGHT" Study

Northwestern University

NCT03419585

COMPLETED NA 75 participants

Evaluating Technology Enabled Services in Perinatal Depression

Northwestern University

NCT05525689

COMPLETED NA 74 participants

Family Promoting Positive Emotions Pilot Study

Vanderbilt University

NCT05223842

COMPLETED NA 74 participants

CAPABLE Family Pilot - Adapting CAPABLE for Older Adults With Mild Cognitive Impairment (MCI)/Early Stage Dementia and Their Care Partners

Johns Hopkins University

NCT05187117

COMPLETED Phase 1 74 participants

Reducing Depression in Dementia Caregivers

University of Missouri, St. Louis

NCT00056316

COMPLETED NA 73 participants

Programmed Environmental Illumination (PEI) of Hospital Rooms to Prevent/Reduce Cancer-Related Fatigue

Icahn School of Medicine at Mount Sinai

NCT03198754

COMPLETED NA 73 participants

A Behavioral Intervention for Depression and Chronic Pain in Primary Care

Weill Medical College of Cornell University

NCT03265210

COMPLETED 73 participants

Clinical and Biological Characteristics of Psychotic Depression

Stanford University

NCT00576095

COMPLETED Phase 4 73 participants

Neurobiological Underpinnings of Placebo Response in Depression

Massachusetts General Hospital

NCT02562430

COMPLETED NA 73 participants

Wraparound for High-risk Families with Substance Use Disorders: Examining Family, Child, and Parent Outcomes

Dartmouth-Hitchcock Medical Center

NCT04637581

COMPLETED 72 participants

Mobile App for Mood in Pregnancy (Ginger iO)

University of Pennsylvania

NCT02761720

COMPLETED NA 71 participants

MEditation for Post Stroke Depression

The University of Texas Health Science Center, Houston

NCT03239132

COMPLETED NA 71 participants

Effectiveness of a Unified Transdiagnostic Treatment in Routine Care

Boston University

NCT02944994

COMPLETED NA 71 participants

Combined Interventions for Treating Depression and Chronic Back Pain

Kaiser Permanente

NCT00158275

COMPLETED 70 participants

Platelet Function in Patients Treated With SSRI and Non-SSRI Antidepressants

National Institutes of Health Clinical Center (CC)

NCT00009568

COMPLETED Phase 1 70 participants

Comparison of Two Psychotherapy Treatments for Depressed Women With a History of Sexual Abuse

University of Rochester

NCT00257400

COMPLETED Phase 2 68 participants

Repeated Partial Sleep Deprivation to Augment SSRI Response in Depression

University of Michigan

NCT01545843

COMPLETED NA 68 participants

Testing a Positive Psychology-based Intervention for Couples Coping With Stroke

University of Utah

NCT03335358

COMPLETED NA 68 participants

Self-guided Depression Treatment on Long-duration Spaceflights: A Continuation Study

Beth Israel Deaconess Medical Center

NCT00906581

COMPLETED Phase 1 67 participants

Rapid Antidepressant Effects of Ketamine in Major Depression

National Institute of Mental Health (NIMH)

NCT00088699

COMPLETED NA 66 participants

Trial of Asthma Self-Management Education in Patients With Depressive Symptoms

Hospital for Special Surgery, New York

NCT01708070

COMPLETED NA 66 participants

Development of a Mind Body Program for Obese Knee Osteoarthritis Patients With Comorbid Depression

University of Kentucky

NCT04334278

COMPLETED NA 64 participants

Effects of Open-label Placebos on COVID-related Psychological Health

Michigan State University

NCT05035550

COMPLETED NA 64 participants

Mindfulness, Yoga, and Cardiovascular Disease

The Cleveland Clinic

NCT00696852

COMPLETED NA 63 participants

Study of a PST-Trained Voice-Enabled Artificial Intelligence Counselor (SPEAC) for Adults With Emotional Distress (Phase 1)

University of Illinois at Chicago

NCT04524104

COMPLETED NA 63 participants

Mental Health Intervention for Elderly Abuse Victims

Weill Medical College of Cornell University

NCT02283385

COMPLETED NA 60 participants

Disseminating Evidence-based Mood Disorder Chronic Care Models

University of Michigan

NCT01615458

COMPLETED NA 60 participants

Preventing Depression and Anxiety: A Cystic Fibrosis-Specific Cognitive Behavioral Therapy Intervention

Massachusetts General Hospital

NCT03992027

COMPLETED Phase 4 60 participants

A Study of Infliximab for Treatment Resistant Major Depression

Emory University

NCT00463580

COMPLETED Phase 2 59 participants

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder

Wyeth is now a wholly owned subsidiary of Pfizer

NCT00619619

COMPLETED NA 59 participants

Cornerstone Program for Transition-Age Youth Study Protocol for a Randomized Controlled Trial

New York University

NCT02696109

COMPLETED Phase 3 58 participants

Rhodiola Rosea Therapy of Major Depressive Disorder

University of Pennsylvania

NCT01098318

COMPLETED NA 57 participants

Neurocognitive Predictors of Behavioral Therapy Response in Depression

Laureate Institute for Brain Research

NCT02602340

COMPLETED 57 participants

Insulin Resistance in Patients With Major Depression

Stanford University

NCT01106313

COMPLETED NA 57 participants

The Treatment of Depression With Yoga and Walking

Boston University

NCT02907476

COMPLETED NA 56 participants

Investigating LIFUP in Anhedonic Depression

University of California, Los Angeles

NCT06285474

COMPLETED Phase 1 56 participants

The Effects of Smell on Mood and Physical Responses

National Center for Complementary and Integrative Health (NCCIH)

NCT00097253

COMPLETED NA 55 participants

Making Better Lives: Patient-Focused Care for Low Back Pain (LBP)

VA Office of Research and Development

NCT02697435

COMPLETED NA 54 participants

Adjunctive Brief Behavioral Treatment of Insomnia (BBTI) for Sleep Intervention (SI)

VA Office of Research and Development

NCT02248675

COMPLETED NA 54 participants

Effectiveness of Cognitive Behavioral Therapy for Treating Depression in People With Bipolar I Disorder

Massachusetts General Hospital

NCT00595387

COMPLETED NA 54 participants

Effects of Mindfulness-based Cognitive Therapy on Brain Mechanisms in Depression

Massachusetts General Hospital

NCT02200341

COMPLETED NA 53 participants

Internet and Telephone Support Intervention for Stroke Caregivers

VA Office of Research and Development

NCT04348851

COMPLETED NA 53 participants

Pilot Study of Annie Text Messaging for Depression Treatment Adherence

VA Office of Research and Development

NCT03930849

COMPLETED NA 52 participants

Behavioral Activation-Rehabilitation to Improve Depressive Symptoms & Physical Function After Acute Respiratory Failure

Johns Hopkins University

NCT03431493

COMPLETED Phase 2 51 participants

Ketamine for the Treatment of Depression in Parkinson's Disease

Yale University

NCT04944017

← Previous Page 11 of 14 Next →

Phase Distribution

PhaseTrial count
Phase 1 41
Phase 2 70
Phase 3 29
Phase 4 41

Named interventions

Most-linked intervention names on Depression records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
29 trials
Ketamine Drug
11 trials
Escitalopram Drug
11 trials
Psilocybin Drug
8 trials
Placebo Other
8 trials
Sertraline Drug
6 trials
Cognitive Behavioral Therapy Behavioral
5 trials
Duloxetine Drug
5 trials

US sites by state

Facility locations filed on Depression trials. A trial with sites in several states counts in each.

California 116 trials
New York 88 trials
Massachusetts 70 trials
Texas 58 trials
Pennsylvania 54 trials
Florida 49 trials
Maryland 42 trials
North Carolina 38 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Depression page

687 registered trials, 245 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Depression condition card totals 687 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.